NCT06186115

Brief Summary

In a pilot study, the investigators recently showed that intraarticular metallic gold microparticles reduce knee osteoarthritis pain for up to two years and found associated significant proteomic changes in serum and synovial fluid within eight weeks. This study aim to evaluate the outcome after intra-articular injection of gold microparticles for hip osteoarthritis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Mar 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 16, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 29, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

March 4, 2024

Completed
28 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2024

Completed
Last Updated

January 30, 2024

Status Verified

January 1, 2024

Enrollment Period

28 days

First QC Date

December 16, 2023

Last Update Submit

January 26, 2024

Conditions

Keywords

Hip osteoarthritisIntra articular goldOutcome

Outcome Measures

Primary Outcomes (1)

  • WOMAC

    Western Ontario and McMaster Universities Arthritis Index, sub-scores for pain, stiffness, and function, containing 24 questions: 5 pain questions, two stiffness questions, and 17 physical function questions.

    2 year

Secondary Outcomes (1)

  • PainDetect

    2 year

Interventions

GoldCOMBINATION_PRODUCT

Intra articular

Also known as: Hyaluronic acid

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Radiographically confirmed moderate hip OA .

You may qualify if:

  • confirmed moderate hip OA (Kellgren-Lawrence grade ≥ 2), pain for more than 3 months, and maximal pain intensity VAS (Visual Analogue Scale, 0-10) ≥ 5 during the last week

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aalborg University Hospital

Aalborg, Region Northern Jutland, 9000, Denmark

Location

Related Publications (3)

  • Rasmussen S, Kjaer Petersen K, Kristiansen MK, Skallerup J, Aboo C, Thomsen ME, Skjoldemose E, Jorgensen NK, Stensballe A, Arendt-Nielsen L. Gold micro-particles for knee osteoarthritis. Eur J Pain. 2022 Apr;26(4):811-824. doi: 10.1002/ejp.1909. Epub 2022 Feb 1.

    PMID: 35076138BACKGROUND
  • Danscher G, Rasmussen S. nanoGold and microGold inhibit autoimmune inflammation: a review. Histochem Cell Biol. 2023 Mar;159(3):225-232. doi: 10.1007/s00418-023-02182-9. Epub 2023 Mar 2.

    PMID: 36864314BACKGROUND
  • Rasmussen S, Frederickson C, Danscher G. Inhibition of Local Inflammation by Implanted Gold: A Narrative Review of the History and Use of Gold. J Rheumatol. 2023 May;50(5):704-705. doi: 10.3899/jrheum.221150. Epub 2023 Mar 15. No abstract available.

    PMID: 36921973BACKGROUND

Related Links

MeSH Terms

Conditions

Osteoarthritis, Hip

Interventions

GoldHyaluronic Acid

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

Metals, HeavyElementsInorganic ChemicalsTransition ElementsMetalsGlycosaminoglycansPolysaccharidesCarbohydrates

Study Officials

  • Sten Rasmussen, MD PhD

    Northern ODD

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sten Rasmussen, MD PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor Head of Department of Clinical Medicine, Aalborg University, Denmark

Study Record Dates

First Submitted

December 16, 2023

First Posted

December 29, 2023

Study Start

March 4, 2024

Primary Completion

April 1, 2024

Study Completion

May 1, 2024

Last Updated

January 30, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will share

After the publication of the study

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Available after publication
Access Criteria
Will be available at VBN Aalborg University

Locations